Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information for Common Stock
Our common stock has been listed on The Nasdaq Global Select Market under the symbol “VIR” since October 11, 2019.
Holders of Record
As of February 16, 2024, there were approximately 135,032,268 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
Dividend Policy
We currently intend to retain future earnings, if any, for use in operation of our business and to fund future growth. We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.
Stock Performance Graph
The following graph shows the total stockholder’s return on an investment of $100 in cash at market close on October 11, 2019 (the first day of trading of our common stock), through December 31, 2023 for (i) our common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. Pursuant to applicable Securities and Exchange Commission, rules, all values assume reinvestment of the full amount of all dividends; however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder return. This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
95
Table of Contents
Date VIR Nasdaq
Composite
Index Nasdaq
Biotechnology
Index
10/11/2019 $ 100.00 $ 100.00 $ 100.00
10/31/2019 $ 100.57 $ 102.92 $ 106.95
12/31/2019 $ 89.69 $ 111.36 $ 120.19
3/31/2020 $ 244.44 $ 95.57 $ 107.67
6/30/2020 $ 292.23 $ 124.84 $ 136.40
9/30/2020 $ 244.86 $ 138.61 $ 135.11
12/31/2020 $ 191.01 $ 159.96 $ 151.06
3/31/2021 $ 365.69 $ 164.41 $ 149.97
6/30/2021 $ 337.23 $ 180.02 $ 163.40
9/30/2021 $ 310.41 $ 179.33 $ 161.40
12/31/2021 $ 298.64 $ 194.18 $ 150.10
3/31/2022 $ 183.45 $ 176.50 $ 132.24
6/30/2022 $ 181.67 $ 136.88 $ 118.99
9/30/2022 $ 137.52 $ 131.26 $ 119.59
12/31/2022 $ 180.53 $ 129.90 $ 133.73
3/31/2023 $ 165.98 $ 151.69 $ 130.94
6/30/2023 $ 174.96 $ 171.13 $ 129.40
9/29/2023 $ 66.83 $ 164.07 $ 125.49
12/29/2023 $ 71.75 $ 186.31 $ 138.72
Securities Authorized for Issuance Under Equity Compensation Plans
The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in PART III Item 12 of this Annual Report on Form 10-K.
Use of Proceeds from Registered Securities
None.
Recent Sales of Unregistered Equity Securities
None.
Issuer Purchases of Equity Securities
None.
Item 6. [Reserved]
96
Table of Contents